HIKMA, A CONVINCINGLY DIFFERENT PHARMA (ADD; 12% UPSIDE)
23/12/20 -"Since our last endorsement in April 2020, it has been a seesaw ride for the generic drugs manufacturer, Hikma (Add, UK). While the reiteration of its FY20 targets (in May), at a time when peers were ..."
Pages
53
Language
English
Published on
23/12/20
You may also be interested by these reports :
07/11/25
Genmab’s Q3 results surpassed the street’s expectations, driven by robust performance across most offerings, resulting in solid profitability ...
07/11/25
All segments performed decently in Q3, though the markets were spooked by Hikma’s mid-term outlook downgrade. Operational delays at the Bedford ...
07/11/25
Novonesis delivered a good Q3 2025, with revenue and adjusted EBITDA beating consensus. Organic sales growth of 6% was driven by broad-based volume ...
06/11/25
The Q3 results surpassed expectations, backed by strong performance from Oncology, Respiratory & Immunology, and Rare Disease medicines. Now, the ...